The company, which was founded in 1999, will use funds for the global expansion of its Timaeus product, a single, purpose-designed intelligent data acquisition and management service.
Timaeus’s advantages over rival systems include rapid set-up and the ability to deal with complex clinical studies, according to the company.
In addition, the offering also operates over low bandwidth, enabling GSM and GPRS wireless connection with remote clinical trial sites, as well as web use.
Timaeus has already been implemented by a number of pharma and biotech companies.
Headquartered in the UK, Cmed also has bases in the US and Romania.